	Item No	Recommendation	Location in study
Title and abstract	1	(a) Indicate the study's design with a commonly used term	Title
		in the title or the abstract	
		(b) Provide in the abstract an informative and balanced	Abstract
		summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	Abstract
-		investigation being reported	
Objectives	3	State specific objectives, including any prespecified	Introduction
		hypotheses	
Methods			
Study design	4	Present key elements of study design early in the paper	Last paragraph Introduction
Setting	5	Describe the setting, locations, and relevant dates, including	Methods
-		periods of recruitment, exposure, follow-up, and data	
		collection	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the	Methods
•		sources and methods of selection of participants. Describe	
		methods of follow-up	
		Case-control study—Give the eligibility criteria, and the	
		sources and methods of case ascertainment and control	
		selection. Give the rationale for the choice of cases and	
		controls	
		Cross-sectional study—Give the eligibility criteria, and the	
		sources and methods of selection of participants	
		(b) Cohort study—For matched studies, give matching	N/A
		criteria and number of exposed and unexposed	
		Case-control study—For matched studies, give matching	
		criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	Methods and Results
		confounders, and effect modifiers. Give diagnostic criteria,	(Limitations)
		if applicable	
Data sources/	8*	For each variable of interest, give sources of data and	Methods
measurement		details of methods of as sessment (measurement). Describe	
		comparability of as sessment methods if there is more than	
		one group	
Bias	9	Describe any efforts to address potential sources of bias	Methods, controls
Study size	10	Explain how the study size was arrived at	N/A
Quantitative	11	Explain how quantitative variables were handled in the	Methods
variables		analyses. If applicable, describe which groupings were	
		chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to	Methods (Statistical
		control for confounding	Analysis)
		(b) Describe any methods used to examine subgroups and	N/A

		interactions	
		(c) Explain how missing data were addressed	Methods
		(d) Cohort study—If applicable, explain how loss to follow-	Methods
		up was addressed	
		Case-control study—If applicable, explain how matching of	
		cases and controls was addressed	
		Cross-sectional study—If applicable, describe analytical	
		methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	Results
		numbers potentially eligible, examined for eligibility,	
		confirmed eligible, included in the study, completing follow-	
		up, and analysed	
		(b) Give reasons for non-participation at each stage	Methods/Results
		(c) Consider use of a flow diagram	
Descriptive	14*	(a) Give characteristics of study participants (eg	Methods/Results
data		demographic, clinical, social) and information on exposures	
		and potential confounders	
		(b) Indicate number of participants with missing data for	N/A
		each variable of interest	
		(c) Cohort study—Summarise follow-up time (eg, average	
		and total amount)	
Outcome data	15*	Cohort study—Report numbers of outcome events or	
		summary measures over time	
		Case-control study—Report numbers in each exposure	
		category, or summary measures of exposure	
		Cross-sectional study—Report numbers of outcome events	N/A
		or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-	Results
		adjusted estimates and their precision (eg, 95% confidence	
		interval). Make clear which confounders were adjusted for	
		and why they were included	
		(b) Report category boundaries when continuous variables	N/A
		were categorized	
		(c) If relevant, consider translating estimates of relative risk	N/A
		into absoluterisk for a meaning ful time period	
Otheranalyses	17	Report other analyses done—eg analyses of subgroups and	N/A
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	Discussion
Limitations	19	Discuss limitations of the study, taking into account sources of	Discussion: Limitations
		potential bias or imprecision. Discuss both direction and	
		magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering	Discussion
-		objectives, limitations, multiplicity of analyses, results from	

		1 .1	1
eımılar	efuldies	and other re	levantevidence

Generalisability	21	Discuss the generalisability (external validity) of the study	Conclusion		
		results			
Other information					
Funding	22	Give the source of funding and the role of the funders for the	N/A		
		present study and, if applicable, for the original study on which			
		the present article is based			

<sup>\*</sup>Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.